Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by First Hawaiian Bank

First Hawaiian Bank increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 18.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,995 shares of the biopharmaceutical company’s stock after purchasing an additional 474 shares during the period. First Hawaiian Bank’s holdings in Regeneron Pharmaceuticals were worth $2,133,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Range Financial Group LLC purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth $220,000. Diversified Trust Co raised its position in Regeneron Pharmaceuticals by 93.0% during the 4th quarter. Diversified Trust Co now owns 2,330 shares of the biopharmaceutical company’s stock worth $1,660,000 after buying an additional 1,123 shares during the last quarter. Nordea Investment Management AB raised its position in Regeneron Pharmaceuticals by 23.6% during the 4th quarter. Nordea Investment Management AB now owns 42,667 shares of the biopharmaceutical company’s stock worth $30,160,000 after buying an additional 8,135 shares during the last quarter. RK Asset Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 9.9% in the fourth quarter. RK Asset Management LLC now owns 9,989 shares of the biopharmaceutical company’s stock worth $7,115,000 after acquiring an additional 896 shares during the period. Finally, Everence Capital Management Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 2.4% during the fourth quarter. Everence Capital Management Inc. now owns 3,831 shares of the biopharmaceutical company’s stock worth $2,729,000 after purchasing an additional 90 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $733.59 on Thursday. The stock has a 50 day moving average price of $756.46 and a 200 day moving average price of $966.75. The stock has a market cap of $80.61 billion, a PE ratio of 18.15, a P/E/G ratio of 2.19 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a one year low of $693.00 and a one year high of $1,211.20.

Analyst Ratings Changes

Several research firms have commented on REGN. Morgan Stanley lowered their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Oppenheimer dropped their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Leerink Partnrs downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Finally, Evercore ISI cut their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,044.48.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.